Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
Authors
Keywords
-
Journal
Immunotherapy
Volume 8, Issue 2, Pages 135-143
Publisher
Future Medicine Ltd
Online
2016-01-19
DOI
10.2217/imt.15.108
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody
- (2015) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin’s lymphomas
- (2015) Maro Ohanian et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
- (2015) Boris Shor et al. MOLECULAR IMMUNOLOGY
- Genomics in acute lymphoblastic leukaemia: insights and treatment implications
- (2015) Kathryn G. Roberts et al. Nature Reviews Clinical Oncology
- Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia
- (2014) Caroline Le Jeune et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook
- (2013) Loretta Sullivan-Chang et al. BIODRUGS
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
- (2013) Hagop Kantarjian et al. CANCER
- Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin
- (2013) Partow Kebriaei et al. Clinical Lymphoma Myeloma & Leukemia
- Novel targeted therapies in acute lymphoblastic leukemia
- (2013) Craig A. Portell et al. LEUKEMIA & LYMPHOMA
- The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
- (2013) Hans-Peter Gerber et al. NATURAL PRODUCT REPORTS
- Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia
- (2013) Michael Rytting et al. PEDIATRIC BLOOD & CANCER
- Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy
- (2012) Stefan Faderl et al. Clinical Lymphoma Myeloma & Leukemia
- Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia
- (2012) Xavier Thomas EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Gemtuzumab Ozogamicin: Time to Resurrect?
- (2012) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia
- (2012) Hagop Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
- (2011) A. D. Ricart CLINICAL CANCER RESEARCH
- Modern Therapy of Acute Lymphoblastic Leukemia
- (2011) Renato Bassan et al. JOURNAL OF CLINICAL ONCOLOGY
- The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells
- (2011) J F de Vries et al. LEUKEMIA
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
- (2011) Sara Raponi et al. LEUKEMIA & LYMPHOMA
- First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
- (2010) F. Ravandi et al. BLOOD
- Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP
- (2010) John F. DiJoseph et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
- (2010) Anjali Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00
- (2010) Renato Bassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia
- (2010) Pier Paolo Piccaluga et al. LEUKEMIA & LYMPHOMA
- Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus
- (2010) Capucine Daridon et al. ARTHRITIS RESEARCH & THERAPY
- CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions
- (2009) Lars Nitschke IMMUNOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation